The New Drug Evaluation for Fluticasone furoate/umeclidinium bromide/vilanterol (Trelegy Ellipta®) for the treatment of COPD is now online. This publication provides a concise, structured evaluation of the efficacy, safety, cost and potential place in therapy for this new product.
Visit our New Drug Evaluations page
Published: Thu, 17 May 2018 14:30:04 +0000
NEW Low priority for NHS funding report with 2017/2018 Q3 data is now available online. This is available to our stakeholders only (username and password required). Access is via the Prescribing Analysis Reports section of this site (Under the Prescribing Analysis Reports menu, click on the ‘Cost Impact and Savings’ menu item followed by the ‘Cost Impact Estimates’ heading). This is an update to the pdf reports we produced in September 2017, the data is now housed in an Excel report providing stakeholders with the same CCG comparator options found in our therapeutic reports (NHS area, Top 10 most similar and User Defined) along with the same range of additional features. We would appreciate any feedback on the content of this report via our contact email address firstname.lastname@example.org
Published: Fri, 11 May 2018 17:38:55 +0000
Drug Tariff monitors for April 2018 are now online. These documents are available to our stakeholders only (username and password required). Access is via the Prescribing Analysis Reports menu, look for 'Drug Tariff Monitor' under the Cost Impact and Savings submenu. Please note, these are large Microsoft Excel Spreadsheets that have been zipped (compressed) to improve download speeds. We recommend saving the files to your computer before attempting to open them. The spreadsheets contain a lot of data and calculations and may take a moment to refresh as you select different options. In the event of any problems it may assist performance if you close any other applications running on your PC.
Published: Fri, 11 May 2018 14:48:38 +0000
May 2018 Monthly Horizon Scanning Report is now available.
Please see our Monthly Horizon Scanning Reports page.
Published: Tue, 08 May 2018 12:19:35 +0000
Our Cost Comparison Charts and Switch Saving Calculators for April 2018 are now available online. The latest Excel, Word and PDF versions of the Cost Comparison Charts are available to our stakeholders only (user and password required). The charts are located here.
The Switch Saving Calculators are also available to stakeholders only. Access is via the Prescribing Analysis Reports menu, under the Cost Impact and Savings submenu item.
Published: Fri, 27 Apr 2018 16:18:53 +0000
February 2018 reports are now online. These documents are available to our stakeholders only (username and passowrd required). Access is via the 'Financial Headlines' link in the Prescribing Analysis Reports section of this site.
Published: Wed, 18 Apr 2018 11:09:18 +0000
NEW Gastro-intestinal draft report with 2017/2018 Q3 data is now available online. This is available to our stakeholders only (username and password required). Access is via the Prescribing Analysis Reports section of this site (Under the Prescribing Analysis Reports menu, click on the 'Therapeutic' menu item followed by the Gastro-intestinal BNF heading). Following stakeholder feedback we have developed this therapeutic report to look at the prescribing of gastro-intestinal drugs. The report has indicators looking at Dyspepsia, Acute Diarrhoea, Anti-secretory drugs and Chronic Bowel Disorders. The report also includes all indicators found in our laxatives report which we will now be retiring. We would appreciate any suggestions or feedback on the content of this report via our contact email address email@example.com
Published: Mon, 16 Apr 2018 11:18:15 +0000
Published: Thu, 12 Apr 2018 11:59:53 +0000
April 2017 to December 2017 Growth Contrast Tool now online. These documents are available to our stakeholders only (username and password required). Access is via the 'Growth Contrast Tool' link in the Prescribing Analysis Reports section of this site.
Published: Thu, 12 Apr 2018 11:29:00 +0000
April 2018 Monthly Horizon Scanning Report is now available.
Please see our Monthly Horizon Scanning Reports page.
Published: Mon, 09 Apr 2018 14:00:30 +0000
NHS England & NHS Clinical Commissioners have published a quick reference guide (QRG) to Conditions for which over the counter items should not routinely be prescribed in primary care. The OTC QRG sets out the reasons for recommending that certain treatments of limited clinical effectiveness, or used for conditions that are either self-limiting or suitable for self-care, should not be routinely prescribed in primary care Continue Reading »Memos and Alerts News Prescribing Newsletter
Published: Tue, 22 May 2018 13:23:14 +0000
In February 2018, the European Medicine Agency Pharmacovigilance Risk Assessment Committee (PRAC) issued temporary recommendations that no new patients should be started on Esmya (ulipristal acetate), following reports of serious injury. The PRAC has completed its review of Esmya. The Committee has now concluded that new patients can start treatment in line with the above recommendations to minimise the risk Continue Reading »Memos and Alerts News Prescribing Newsletter fibroids liver injury safety ulipristal uterine fibroids
Published: Tue, 22 May 2018 11:48:48 +0000
Following recommendations in the report of the Short Life Working Group on reducing medication-related harm, the Department of Health & Social Care Medicines Safety Programme has developed an open-access Medication Safety Dashboard with a series of preliminary prescribing indicators. A more granular & detailed version of the Medication Safety Dashboard is available via EPACT2. The aim of the indicators is to: Continue Reading »Memos and Alerts News Prescribing Newsletter
Published: Mon, 14 May 2018 17:24:55 +0000
The Department of Health & Social Care has issued the following advice via the Central Alerting System: The most recent surveillance data from Public Health England (PHE) indicates that circulation of influenza in the community has returned to baseline levels. GPs and other prescribers working in primary care should no longer prescribe antiviral medicines, for the prophylaxis and Continue Reading »Memos and Alerts News
Published: Mon, 14 May 2018 17:14:44 +0000
The Academic Health Science Network for the North East & North Cumbria have refreshed the Anticoagulant Treatment in Atrial Fibrillation Card Deck distributed to GPs across the region in 2017. The refreshed Card Deck, produced jointly with Northern England Clinical Networks and endorsed by the Atrial Fibrillation Association and the Stroke Association, has been designed to help GPs manage AF more effectively. The Continue Reading »Cardiovascular News Prescribing Newsletter
Published: Wed, 09 May 2018 13:48:07 +0000
Valproate medicines must no longer be used in women or girls of childbearing potential unless a Pregnancy Prevention Programme is in place.
We are aware of reports of serious liver injuries and deaths in patients with primary biliary cholangitis with pre-existing moderate or severe liver impairment who were not adequately dose-adjusted.
Any healthcare professional can submit a Yellow Card, including students.
Letters were sent to healthcare professionals about Zinbryta▼ (daclizumab beta), Lynparza 50 mg capsules, and radium-223-dichloride (Xofigo▼).
An alert was issued about T34 ambulatory syringe pumps.
The European Medicines Agency (EMA) has recommended the immediate suspension of the marketing authorisation and recall of daclizumab (Zinbryta) in the EU following reports of serious inflammatory brain disorders, including encephalitis and meningoencephalitis, in patients with multiple sclerosis.
Temporary safety measures are in place while an EU review investigates the link between cases of serious liver injury, including 4 cases requiring liver transplantation, and Esmya for uterine fibroids.
Pharmacists should tell people about the risk of fire when they discuss head lice eradication options.
Confidential reports designed to help you improve the quality of your prescribing and patient safety are now available for practices that contribute to the MHRA’s Clinical Practice Research Datalink.
Letters were sent about ellaOne, ERWINASE, Eperzan▼, Ocaliva▼, Velcade, Esmya, and Bleo-Kyowa.
Northern Treatment Advisory Group: http://ntag.nhs.uk/html/latest_news.html